Technetium Tc-99m medronate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Technetium Tc-99m medronate
Accession Number
DB09138
Type
Small Molecule
Groups
Approved
Description

Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate. Like other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of altered osteogenesis. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.

Structure
Thumb
Synonyms
  • 99m Tc medronate
  • 99m Tc-medronate
  • 99mTc medronate
  • 99mTc-medronate
  • AN-MDP
  • Cis-Mdp
  • Tc 99m Mdp
  • Tc-99m Mdp
  • Technetium (99mTc) medronic acid
  • Technetium (99mTc) Methylenediphosphonate
  • Technetium 99mTc medronic acid
  • Technetium methylene diphosphonate
  • Technetium Tc 99m medronate
  • Technetium Tc 99m medronic acid
  • Technetium Tc 99M Mpi Mdp
Product Ingredients
IngredientUNIICASInChI Key
Technetium Tc-99m medronate disodiumV3V5VW82PO65871-22-9AXNBRPOESGBANA-KTTJZPQESA-F
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Kit for the Preparation of Technetium Tc 99M MedronateInjection, powder, lyophilized, for solution20 mg/10mLIntravenousPharmalucence, Inc.1979-08-29Not applicableUs
MDP-BraccoInjection, powder, lyophilized, for solution20 mg/1IntravenousBracco Diagnostics, Inc1981-02-172015-05-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
X89XV46R07
CAS number
121524-79-6
Weight
Average: 305.906
Monoisotopic: 305.861006841
Chemical Formula
CH6O8P2Tc
InChI Key
IUPNVOAUFBLQME-SGNQUONSSA-J
InChI
InChI=1S/CH6O6P2.2H2O.Tc/c2-8(3,4)1-9(5,6)7;;;/h1H2,(H2,2,3,4)(H2,5,6,7);2*1H2;/q;;;+4/p-4/i;;;1+1
IUPAC Name
(⁹⁸Tc)technetium(4+) ion dihydrate (phosphonatomethyl)phosphonate
SMILES
O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O

Pharmacology

Indication

Technetium Tc 99m Medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

When injected intravenously, Technetium Tc 99m Medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. About 10% of the injected dose remains in the blood at 1 hour post-injection, 5% at 2 hours, and less than 1% remains at 24 hours. Following intravenous administration of Technetium Tc 99m Medronate, skeletal uptake occurs as a function of blood flow to bone and bone efficiency in extracting the complex.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Technetium Tc-99m decays by isomeric transition with a physical half-life of 6.02 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Jiang RF, Zhang L, Cheng B, Huang Z, Li DL, Wang MM, Lu XT, Zhang YX, Cao W: Increased uptake of Tc-99m-methylene diphosphonate in the jaw. Clin Imaging. 2015 Nov-Dec;39(6):1068-72. doi: 10.1016/j.clinimag.2015.06.009. Epub 2015 Jul 16. [PubMed:26318916]
  2. Yang F, Yang Z, Feng J, Zhang L, Ma D, Yang J: Three phase bone scintigraphy with (99m)Tc-MDP and serological indices in detecting infection after internal fixation in malunion or nonunion traumatic fractures. Hell J Nucl Med. 2016 May-Aug;19(2):130-4. doi: 10.1967/s002449910366. Epub 2016 Jun 22. [PubMed:27331206]
  3. Ballani NS, Al-Huda FA, Khan HA, Al-Mohannadi S, Mahmood H, Al-Enezi F: The value of quantitative uptake of (99m)Tc-MDP and (99m)Tc-HMPAO white blood cells in detecting osteomyelitis in violated peripheral bones. J Nucl Med Technol. 2007 Jun;35(2):91-5. Epub 2007 May 11. [PubMed:17496004]
External Links
KEGG Drug
D02029
PubChem Compound
131704315
PubChem Substance
310265053
ChemSpider
34995234
ChEBI
32186
ChEMBL
CHEMBL2110576
Wikipedia
Technetium_(99mTc)_medronic_acid
ATC Codes
V09BA02 — Technetium (99mtc) medronic acid
FDA label
Download (1.68 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Enrolling by InvitationDiagnosticSkeletal injury1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous20 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous20 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.5 mg/mLALOGPS
logP1.03ALOGPS
logP-2.4ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)1.27ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.38 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity23.39 m3·mol-1ChemAxon
Polarizability10.06 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on September 30, 2015 10:19 / Updated on July 13, 2019 00:52